The mu opioid receptor is implicated in the reward, tolerance and with
drawal effects of alcohol and other drugs of abuse.(1,2) This hypothes
is is supported by the effects of alcohol on beta-endorphin release,(3
) of mu opioid receptor agonists and antagonists on alcohol consumptio
n,(4,5) and by the activation of the dopaminergic reward system by bot
h alcohol and opiates.(6) In addition, the murine mu opioid receptor l
ocus, Oprm, is implicated as the major quantitative trait locus (QTL)
affecting the different levels of morphine consumption between two inb
red mouse strains that also exhibit differences in alcohol and cocaine
consumption.(7,8) Detection of genetic variation affecting OPRM1 expr
ession or mu opioid receptor function would be an important step towar
ds understanding the origins of inter-individual variation in response
to mu opioid receptor ligands and in diseases of substance dependence
.(9-12) We directly sequenced the human mu opioid receptor locus, OPRM
1,(13-15) to detect natural variation that might affect function and/o
r be associated with psychiatric phenotypes related to opioid function
. Four DNA sequence variants were found: three non-synonymous substitu
tions (Ala6Val [rare], Asn40Asp, [0.10-0.16], Ser147Cys [rare]) and on
e intronic variant (IVS2+691G/C [0.55-0.63]). OPRM1 alleles, genotypes
and haplotypes from three psychiatrically characterized population sa
mples (US Caucasian [USC, n = 100], Finnish Caucasian [FC, n = 324] an
d Southwestern American Indian [SAI, n = 367]), were used to perform a
ssociation and sib-pair linkage analyses with alcohol and drug depende
nce diagnoses. No significant association of OPRM1 genetic variation t
o phenotype was observed. This analysis has 80% power to detect a smal
l to moderate effect of OPRM1 variation on alcohol dependence and 100%
power to detect effects of the magnitude of the ALDH22 variant. Whil
e these data do not support a role of the mu opioid receptor in suscep
tibility to alcohol dependence, the potential relationship between OPR
M1 genetic variation and response to endogenous opioids and exogenous
opiates can now be investigated.